Literature DB >> 22162127

Estimation and testing of the relative risk of disease in case-control studies with a set of k matched controls per case with known prevalence of disease.

Barry Kurt Moser1, Susan Halabi.   

Abstract

The analysis of case-control studies with matched controls per case is well documented in the medical literature. Of primary interest is the estimation of the relative risk of disease. Matched case-control studies fall into two scenarios: the probability of exposure is constant within each of the case and control groups, or the probability of exposure varies within each group. Numerous estimation procedures have been developed for both scenarios. Often these procedures are developed under the rare disease assumption, where the relative risk of disease is approximated by the odds ratio. In this paper, without making the rare disease assumption, we develop consistent estimators of the relative risk of disease for both scenarios. Exact derivations of the relative risk of disease are provided. Estimators, confidence intervals, and test statistics for the relative risk of disease are developed. We then make the following observations based on extensive simulations. First, our estimators are as close or closer to the relative risk of disease than other estimators. Second, our estimators produce mean square errors for the relative risk of disease that are as good as or better than these other estimators. Third, our confidence intervals provide accurate coverage probabilities. Therefore, these new estimators, confidence intervals, and test statistics can be used to either estimate or test the relative risk of disease in matched case-control studies.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22162127      PMCID: PMC3637965          DOI: 10.1002/sim.4414

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  19 in total

1.  Estimating the relative risk in cohort studies and clinical trials of common outcomes.

Authors:  Louise-Anne McNutt; Chuntao Wu; Xiaonan Xue; Jean Paul Hafner
Journal:  Am J Epidemiol       Date:  2003-05-15       Impact factor: 4.897

2.  Calculating the prevalence of cancer.

Authors:  A J Coldman; M L McBride; T Braun
Journal:  Stat Med       Date:  1992-09-15       Impact factor: 2.373

3.  Simple optimal weighting of cases and controls in case-control studies.

Authors:  Sherri Rose; Mark J van der Laan
Journal:  Int J Biostat       Date:  2008-09-29       Impact factor: 0.968

4.  A method of estimating comparative rates from clinical data; applications to cancer of the lung, breast, and cervix.

Authors:  J CORNFIELD
Journal:  J Natl Cancer Inst       Date:  1951-06       Impact factor: 13.506

5.  What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes.

Authors:  J Zhang; K F Yu
Journal:  JAMA       Date:  1998-11-18       Impact factor: 56.272

6.  Estimation of relative risk from matched pairs in epidemiologic research.

Authors:  A Ejigou; R McHugh
Journal:  Biometrics       Date:  1977-09       Impact factor: 2.571

7.  Multivariate analysis for matched case-control studies.

Authors:  T R Holford; C White; J L Kelsey
Journal:  Am J Epidemiol       Date:  1978-03       Impact factor: 4.897

8.  Are there two logistic regressions for retrospective studies?

Authors:  N Breslow; W Powers
Journal:  Biometrics       Date:  1978-03       Impact factor: 2.571

9.  Estimation of multiple relative risk functions in matched case-control studies.

Authors:  N E Breslow; N E Day; K T Halvorsen; R L Prentice; C Sabai
Journal:  Am J Epidemiol       Date:  1978-10       Impact factor: 4.897

10.  Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.

Authors:  Judy E Garber; Susan Halabi; Sara M Tolaney; Ellen Kaplan; Laura Archer; James N Atkins; Stephen Edge; Charles L Shapiro; Lynn Dressler; Electra D Paskett; Electra M Paskett; Gretchen Kimmick; James Orcutt; Anthony Scalzo; Eric Winer; Ellis Levine; Nasir Shahab; Nancy Berliner
Journal:  J Natl Cancer Inst       Date:  2010-06-16       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.